Single dose oral sulindac for acute postoperative pain in adults.

BACKGROUND: Sulindac is a non-steroidal anti-inflammatory drug (NSAID) licensed for use in rheumatic disease and other musculoskeletal disorders in the UK, and widely available in other countries worldwide. This review sought to evaluate the efficacy and safety of oral sulindac in acute postoperativ...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Moore, R, Derry, S, McQuay, H
Fformat: Journal article
Iaith:English
Cyhoeddwyd: 2009
_version_ 1826300918883155968
author Moore, R
Derry, S
McQuay, H
author_facet Moore, R
Derry, S
McQuay, H
author_sort Moore, R
collection OXFORD
description BACKGROUND: Sulindac is a non-steroidal anti-inflammatory drug (NSAID) licensed for use in rheumatic disease and other musculoskeletal disorders in the UK, and widely available in other countries worldwide. This review sought to evaluate the efficacy and safety of oral sulindac in acute postoperative pain, using clinical studies of patients with established pain, and with outcomes measured primarily over 6 hours using standard methods. This type of study has been used for many decades to establish that drugs have analgesic properties. OBJECTIVES: To assess the efficacy of single dose oral sulindac in acute postoperative pain, and any associated adverse events. SEARCH STRATEGY: We searched Cochrane CENTRAL, MEDLINE, EMBASE and the Oxford Pain Relief Database for studies up to June 2009. SELECTION CRITERIA: Randomised, double-blind, placebo-controlled clinical trials of oral sulindac for relief of acute postoperative pain in adults. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted data. We planned to use area under the "pain relief versus time" curve to derive the proportion of participants with meloxicam experiencing least 50% pain relief over 4 to 6 hours, using validated equations; to use number needed to treat to benefit (NNT); the proportion of participants using rescue analgesia over a specified time period; time to use of rescue analgesia; information on adverse events and withdrawals. MAIN RESULTS: No studies were identified by the searches that examined oral sulindac in patients with established postoperative pain. AUTHORS' CONCLUSIONS: In the absence of evidence of efficacy, at present, for oral sulindac in acute postoperative pain, its use in this indication is not justified. Because trials clearly demonstrating analgesic efficacy in the most basic of acute pain studies is lacking, use in other indications should be evaluated carefully. Given the large number of available drugs of this and similar classes, there is no urgent research agenda.
first_indexed 2024-03-07T05:24:27Z
format Journal article
id oxford-uuid:e015f6f1-a28c-4a02-b9b0-a7303a57aca5
institution University of Oxford
language English
last_indexed 2024-03-07T05:24:27Z
publishDate 2009
record_format dspace
spelling oxford-uuid:e015f6f1-a28c-4a02-b9b0-a7303a57aca52022-03-27T09:44:13ZSingle dose oral sulindac for acute postoperative pain in adults.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e015f6f1-a28c-4a02-b9b0-a7303a57aca5EnglishSymplectic Elements at Oxford2009Moore, RDerry, SMcQuay, HBACKGROUND: Sulindac is a non-steroidal anti-inflammatory drug (NSAID) licensed for use in rheumatic disease and other musculoskeletal disorders in the UK, and widely available in other countries worldwide. This review sought to evaluate the efficacy and safety of oral sulindac in acute postoperative pain, using clinical studies of patients with established pain, and with outcomes measured primarily over 6 hours using standard methods. This type of study has been used for many decades to establish that drugs have analgesic properties. OBJECTIVES: To assess the efficacy of single dose oral sulindac in acute postoperative pain, and any associated adverse events. SEARCH STRATEGY: We searched Cochrane CENTRAL, MEDLINE, EMBASE and the Oxford Pain Relief Database for studies up to June 2009. SELECTION CRITERIA: Randomised, double-blind, placebo-controlled clinical trials of oral sulindac for relief of acute postoperative pain in adults. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted data. We planned to use area under the "pain relief versus time" curve to derive the proportion of participants with meloxicam experiencing least 50% pain relief over 4 to 6 hours, using validated equations; to use number needed to treat to benefit (NNT); the proportion of participants using rescue analgesia over a specified time period; time to use of rescue analgesia; information on adverse events and withdrawals. MAIN RESULTS: No studies were identified by the searches that examined oral sulindac in patients with established postoperative pain. AUTHORS' CONCLUSIONS: In the absence of evidence of efficacy, at present, for oral sulindac in acute postoperative pain, its use in this indication is not justified. Because trials clearly demonstrating analgesic efficacy in the most basic of acute pain studies is lacking, use in other indications should be evaluated carefully. Given the large number of available drugs of this and similar classes, there is no urgent research agenda.
spellingShingle Moore, R
Derry, S
McQuay, H
Single dose oral sulindac for acute postoperative pain in adults.
title Single dose oral sulindac for acute postoperative pain in adults.
title_full Single dose oral sulindac for acute postoperative pain in adults.
title_fullStr Single dose oral sulindac for acute postoperative pain in adults.
title_full_unstemmed Single dose oral sulindac for acute postoperative pain in adults.
title_short Single dose oral sulindac for acute postoperative pain in adults.
title_sort single dose oral sulindac for acute postoperative pain in adults
work_keys_str_mv AT moorer singledoseoralsulindacforacutepostoperativepaininadults
AT derrys singledoseoralsulindacforacutepostoperativepaininadults
AT mcquayh singledoseoralsulindacforacutepostoperativepaininadults